ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Half Of Mexican-Origin Women With Breast Cancer Diagnosed Before Age 50, Study Finds

September 24, 2010

UCSF Gets $20 Million For Stem Cell Research Building

February 4, 2011

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Funding Opportunities: Career Development Award In Leukemia

July 23, 1999

OCC Proposes Plan To Educate Patients, Physicians On Value Of Clinical Trials

January 8, 1988

Breast Cancer Risk Prediction Improved In Atypia Cases

July 27, 2007